vs
Side-by-side financial comparison of Electromed, Inc. (ELMD) and SOLESENCE, INC. (SLSN). Click either name above to swap in a different company.
Electromed, Inc. is the larger business by last-quarter revenue ($18.9M vs $12.5M, roughly 1.5× SOLESENCE, INC.). Electromed, Inc. runs the higher net margin — 14.6% vs 1.3%, a 13.3% gap on every dollar of revenue. On growth, Electromed, Inc. posted the faster year-over-year revenue change (16.3% vs -0.7%). Over the past eight quarters, Electromed, Inc.'s revenue compounded faster (16.7% CAGR vs 12.5%).
Electromed, Inc. is a specialized medical device firm developing, manufacturing, and distributing advanced respiratory care products. Its core offerings are high-frequency chest wall oscillation systems that clear airway secretions for patients with cystic fibrosis, COPD and other respiratory conditions, serving U.S. home care and clinical customers.
ELMD vs SLSN — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.9M | $12.5M |
| Net Profit | $2.8M | $163.0K |
| Gross Margin | 78.4% | 27.5% |
| Operating Margin | 19.2% | 1.5% |
| Net Margin | 14.6% | 1.3% |
| Revenue YoY | 16.3% | -0.7% |
| Net Profit YoY | 40.3% | 129.2% |
| EPS (diluted) | $0.32 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.9M | $12.5M | ||
| Q3 25 | $16.9M | $14.6M | ||
| Q2 25 | $17.4M | $20.4M | ||
| Q1 25 | $15.7M | $14.6M | ||
| Q4 24 | $16.3M | $12.6M | ||
| Q3 24 | $14.7M | $16.9M | ||
| Q2 24 | $14.8M | $13.0M | ||
| Q1 24 | $13.9M | $9.9M |
| Q4 25 | $2.8M | $163.0K | ||
| Q3 25 | $2.1M | $-1.1M | ||
| Q2 25 | $2.2M | $2.7M | ||
| Q1 25 | $1.9M | $80.0K | ||
| Q4 24 | $2.0M | $-559.0K | ||
| Q3 24 | $1.5M | $3.0M | ||
| Q2 24 | $1.8M | $856.0K | ||
| Q1 24 | $1.5M | $893.0K |
| Q4 25 | 78.4% | 27.5% | ||
| Q3 25 | 78.1% | 23.1% | ||
| Q2 25 | 78.3% | 28.9% | ||
| Q1 25 | 78.0% | 23.1% | ||
| Q4 24 | 77.7% | 22.0% | ||
| Q3 24 | 78.3% | 36.2% | ||
| Q2 24 | 76.2% | 28.7% | ||
| Q1 24 | 74.8% | 36.3% |
| Q4 25 | 19.2% | 1.5% | ||
| Q3 25 | 15.8% | -5.4% | ||
| Q2 25 | 17.5% | 9.4% | ||
| Q1 25 | 13.6% | 1.8% | ||
| Q4 24 | 15.6% | -1.8% | ||
| Q3 24 | 13.2% | 19.0% | ||
| Q2 24 | 15.7% | 8.0% | ||
| Q1 24 | 13.3% | 11.3% |
| Q4 25 | 14.6% | 1.3% | ||
| Q3 25 | 12.6% | -7.7% | ||
| Q2 25 | 12.7% | 13.1% | ||
| Q1 25 | 12.1% | 0.5% | ||
| Q4 24 | 12.1% | -4.4% | ||
| Q3 24 | 10.0% | 18.1% | ||
| Q2 24 | 12.3% | 6.6% | ||
| Q1 24 | 10.8% | 9.0% |
| Q4 25 | $0.32 | $0.00 | ||
| Q3 25 | $0.25 | $-0.02 | ||
| Q2 25 | $0.26 | $0.04 | ||
| Q1 25 | $0.21 | $0.00 | ||
| Q4 24 | $0.22 | $0.00 | ||
| Q3 24 | $0.16 | $0.04 | ||
| Q2 24 | $0.20 | $0.01 | ||
| Q1 24 | $0.17 | $0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $13.8M | $1.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $45.4M | $17.6M |
| Total Assets | $54.9M | $50.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $13.8M | $1.3M | ||
| Q3 25 | $14.1M | $429.0K | ||
| Q2 25 | $15.3M | $4.1M | ||
| Q1 25 | $15.2M | $1.8M | ||
| Q4 24 | $16.2M | $1.4M | ||
| Q3 24 | $13.9M | $2.9M | ||
| Q2 24 | $16.1M | $2.4M | ||
| Q1 24 | $11.7M | $2.0M |
| Q4 25 | $45.4M | $17.6M | ||
| Q3 25 | $44.7M | $17.2M | ||
| Q2 25 | $43.2M | $18.2M | ||
| Q1 25 | $43.9M | $15.2M | ||
| Q4 24 | $43.6M | $14.9M | ||
| Q3 24 | $41.5M | $15.2M | ||
| Q2 24 | $44.5M | $11.9M | ||
| Q1 24 | $42.5M | $5.0M |
| Q4 25 | $54.9M | $50.1M | ||
| Q3 25 | $53.6M | $54.0M | ||
| Q2 25 | $53.8M | $60.0M | ||
| Q1 25 | $52.5M | $57.0M | ||
| Q4 24 | $52.3M | $50.0M | ||
| Q3 24 | $48.9M | $48.0M | ||
| Q2 24 | $52.2M | $40.8M | ||
| Q1 24 | $48.9M | $38.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.0M | $1.8M |
| Free Cash FlowOCF − Capex | $2.4M | — |
| FCF MarginFCF / Revenue | 12.7% | — |
| Capex IntensityCapex / Revenue | 3.4% | — |
| Cash ConversionOCF / Net Profit | 1.10× | 11.16× |
| TTM Free Cash FlowTrailing 4 quarters | $7.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.0M | $1.8M | ||
| Q3 25 | $169.0K | $-2.5M | ||
| Q2 25 | $3.9M | $-654.0K | ||
| Q1 25 | $2.1M | $-7.2M | ||
| Q4 24 | $3.2M | $2.2M | ||
| Q3 24 | $2.3M | $4.2M | ||
| Q2 24 | $4.5M | $-565.0K | ||
| Q1 24 | $1.4M | $-3.9M |
| Q4 25 | $2.4M | — | ||
| Q3 25 | $-83.0K | — | ||
| Q2 25 | $3.7M | — | ||
| Q1 25 | $1.9M | — | ||
| Q4 24 | $2.9M | $-404.0K | ||
| Q3 24 | $2.3M | $2.8M | ||
| Q2 24 | $4.5M | $-1.0M | ||
| Q1 24 | $1.3M | $-3.9M |
| Q4 25 | 12.7% | — | ||
| Q3 25 | -0.5% | — | ||
| Q2 25 | 21.4% | — | ||
| Q1 25 | 12.2% | — | ||
| Q4 24 | 18.0% | -3.2% | ||
| Q3 24 | 15.5% | 16.6% | ||
| Q2 24 | 30.1% | -8.0% | ||
| Q1 24 | 9.1% | -39.9% |
| Q4 25 | 3.4% | — | ||
| Q3 25 | 1.5% | — | ||
| Q2 25 | 0.8% | — | ||
| Q1 25 | 1.0% | — | ||
| Q4 24 | 1.4% | 20.6% | ||
| Q3 24 | 0.3% | 8.3% | ||
| Q2 24 | 0.1% | 3.7% | ||
| Q1 24 | 0.6% | 0.9% |
| Q4 25 | 1.10× | 11.16× | ||
| Q3 25 | 0.08× | — | ||
| Q2 25 | 1.75× | -0.25× | ||
| Q1 25 | 1.10× | -90.26× | ||
| Q4 24 | 1.60× | — | ||
| Q3 24 | 1.57× | 1.38× | ||
| Q2 24 | 2.46× | -0.66× | ||
| Q1 24 | 0.90× | -4.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ELMD
| Homecare | $17.3M | 91% |
| Other | $1.6M | 9% |
SLSN
Segment breakdown not available.
